Navigation Links
PneumRx, Inc. Raises $33 Million in Capital
Date:1/4/2011

MOUNTAIN VIEW, Calif., Jan. 4, 2011 /PRNewswire/ -- PneumRx, Inc. (www.pneumrx.com), a medical device company dedicated to bringing innovation and improvements to the treatment of lung disease, today announced that it has raised $33 million in working capital commitments.  The oversubscribed round was led by Forbion Capital Partners and co-led by Endeavour Vision, both leading venture capital firms from Europe, and also included a prominent strategic corporate partner.  The syndicate was joined by existing investors Adams Street Partners, Telegraph Hill Partners, Alta Partners, and Spray Venture Partners, among others.  Silicon Valley Bank and Leader Ventures also contributed to the capital raise in PneumRx.

PneumRx recently established a subsidiary in Germany, PneumRx GmbH, and has begun selling its innovative RePneu Lung Volume Reduction Coil (LVRC) System in Europe. It plans to use the funds to expand European commercialization and to conduct an FDA-approved pivotal clinical trial to support a PMA application.  PneumRx expects to begin its pivotal clinical trial in early 2011 and intends to submit its pivotal trial results to support a PMA application to be able to sell the RePneu LVRC System in the United States.

The RePneu LVRC System is a minimally invasive device intended to improve lung function in emphysema patients by bronchoscopically implanting Nitinol coils into the lungs to compress damaged tissue (lung volume reduction) and restore elastic recoil to the lung.  This treatment offers a minimally invasive alternative to lung volume reduction surgery, and works independently of collateral ventilation.  More than 1500 LVR Coils have been implanted to date in over 170 procedures.  The LVRC System is CE Marked and is currently available in select markets in Europe, with plans for broader expansion.

"We are thrilled to have completed our Series C round and are pleased to add a top-tier med-tech corporate partner in this later financing round.  We believe that this partnership will be extremely beneficial as PneumRx prepares for its future pivotal trial, commercialization and reimbursement efforts in the US.  We also appreciate the addition of two prominent European venture firms to our board.  We look forward to working more closely with Forbion and Endeavour Vision as we expand our commercial efforts in Europe," said Erin McGurk, Founder, President and CEO of PneumRx, Inc.  "2010 was an exciting year for PneumRx, receiving our CE Mark and achieving our first European sales and we look forward to expanding into the US in 2011, with our plans for our pivotal clinical trial.  We are pleased to be able to bring our RePneu Lung Volume Reduction Coil treatment to a greater number of emphysema patients suffering from this debilitating disease."

Martien van Osch, Managing Partner at Forbion Capital Partners said, "PneumRx brings an effective therapy for a large group of emphysema patients. For most of these patients there are, to date, no good treatment alternatives.  Over 1500 coils have been implanted to date and the safety and efficacy profile is very exciting. We are proud to lead this current financing round and to help the company establish a presence and commercial infrastructure in Europe."

Daniel Bertholet, Investment Director at Endeavour Vision, commented, "Having reviewed all the companies in this sector, I am convinced that PneumRx has developed the most promising Lung Volume Reduction device to treat emphysema patients and is likely to become the preferred clinical option in a few years.  We are delighted to join the company in order to support both the European market launch and the pivotal clinical study."

Martien van Osch and Daniel Bertholet will both join the Board of Directors.

About PneumRx, Inc.

PneumRx, Inc. is a rapidly growing medical device company focused on the development and commercialization of innovative products to treat emphysema using minimally-invasive techniques.  It is a privately held company located in Mountain View, California.  For more information, please visit www.pneumrx.com.

About Forbion Capital Partners

Forbion Capital Partners is a dedicated Life Sciences venture capital firm with offices in Naarden, The Netherlands, and Munich, Germany. For more information, please visit www.forbion.com.

About Endeavour Vision

Endeavour Vision, located in Geneva, Switzerland, is a venture capital investment firm which globally invests in both the Life Sciences and Information/Communication Technology sectors.  For more information, please visit www.endeavourvision.com.


'/>"/>
SOURCE PneumRx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PneumRx, Inc. Announces CE Mark Approval for Its RePneu® Lung Volume Reduction Coil (LVRC™) System
2. U.S. FDA Approves Second Bayer Oral Contraceptive That Also Raises Folate Levels
3. Sofie Biosciences Raises $2M to Support Development of Diagnostic Imaging Agents and Devices
4. CardioGenics Raises $1.9 Million in Private Placement
5. Perrigo Reports Record Earnings and Raises Full Year Adjusted EPS Guidance
6. U.S. FDA Approves New Oral Contraceptive That Also Raises Folate Levels
7. immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio
8. Dyadic International Raises Additional $1 Million to Complete $4 Million Convertible Note Offering
9. StatRad Raises the Bar With Fully Integrated Teleradiology Solution
10. HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing
11. AVAC Praises CAPRISA 004 Trial Collaborators and Participants for Historic Study - Trial Confirms Promise of ARV-Based Microbicides
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... markets and sells medical devices and wearable sleep respiratory ... strategic cooperation agreement with Hongyuan Supply Chain Management Co., ... June 20, 2016, to develop Dehaier,s new Internet medical ... Dehaier will leverage Hongyuan Supply Chain,s sales platform to ...
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, ... dedicated to helping service members that have been wounded in battle and their families. ...
Breaking Medicine News(10 mins):